|
시장보고서
상품코드
2039115
재발성 교모세포종 치료 시장 : 치료법별, 유형별, 지역별Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, By Type, By Geography |
||||||
재발성 교모세포종 치료 시장은 2026년에 35억 달러로 추정되며, 2033년까지 53억 7,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR은 8.35%를 보일 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 35억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 8.35% | 예측 금액(2033년) | 53억 7,000만 달러 |
다형성 교모세포종(GBM)은 신경교세포에서 유래한 공격성이 높은 가장 흔한 뇌종양의 일종입니다. 신경교종은 척수나 뇌에 존재하는 별 모양의 신경교세포에서 발생하며 빠르게 증식하는 종양입니다. 재발성 다형성 교모세포종 치료는 종양 수술 후 GBM이 재발할 가능성이 있는 경우를 말합니다. 이는 수술 중 종양을 완전히 절제하기 어렵고, 관해 기간이 지나면 암이 재발할 가능성이 있기 때문입니다. GBM의 증상으로는 지속적인 두통, 발작, 구토, 언어장애, 복시, 시력저하 등이 있습니다.
시장 역학
뇌종양 발생률 증가는 예측 기간 동안 재발성 다형성 교모세포종 치료제 시장을 견인할 것으로 예측됩니다. 연구진은 유전자 변이가 이 질환의 원인일 수 있다고 보고 있으며, 증상으로는 발작, 기분 변화, 식욕 부진, 복시 및 시야 흐림, 사고 능력의 변화, 언어 장애 등이 있습니다. 세계보건기구(WHO)의 통계에 따르면, 전 세계적으로 매년 약 500만 명이 간질 진단을 받고 있습니다.
또한, 결절성 경화증, 신경섬유종증, 폰 히펠 린다우병, 터코트 증후군, 리-프라우메니 증후군 등은 유전성 질환 중 일부로, 글리오마 유병률 증가와 연관된 유전성 질환으로 예측 기간 동안 시장 성장을 견인할 것으로 예측됩니다.
또한, 시장의 주요 기업들은 신약 개발, 창출 및 상용화를 위한 연구개발에 대한 투자를 확대하고 있으며, 이는 가까운 미래에 세계 재발성 다형성 교모세포종 치료제 시장에 유망한 성장 기회를 제공할 것으로 예측됩니다. 그러나 효과적인 치료법의 부족과 약물에 의한 종양 재발을 효과적으로 예방하기 어렵다는 점이 예측 기간 동안 시장 성장을 제약할 것으로 예측됩니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 재발성 다형성 교모세포종 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등 다양한 매개변수를 기반으로 정리하여 전해드립니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 재발성 다형성 교모세포종 치료 시장' 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 재발성 교모세포종 치료 시장 : 치료법별(2026년-2033년)
제5장 세계의 재발성 교모세포종 치료 시장 : 유형별(2026년-2033년)
제6장 세계의 재발성 교모세포종 치료 시장 : 지역별(2026년-2033년)
제7장 경쟁 구도
제8장 섹션
LSH 26.06.04Recurrent Glioblastoma Multiforme Treatment Market is estimated to be valued at USD 3.5 Bn in 2026 and is expected to reach USD 5.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.35% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.35% | 2033 Value Projection: | USD 5.37 Bn |
Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.
Market Dynamics
The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.
Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.
Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
- Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- By Treatment
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type
- Grade II or Grade III
- Grade IV
- Others
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- GlaxoSmithKline plc.
- AstraZeneca
- Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Oral Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Radiosensitizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Nitrosoureas Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Grade II or Grade III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Grade IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffman-La Roche, Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Vascular Biogeneics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AngioChem, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Boston Biomedical, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cantex Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Celldex Therapeutics, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cavion LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cavion LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eisai
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cortice Biosciences, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- EnGeneIC Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- GenSpera, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- ERC Belgium SA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- Genzyme Corporation
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- ImmunoCellular Therapeutics, Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- GW Pharmaceuticals Plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
(주말 및 공휴일 제외)
